TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00503152
Drug: Benazepril
Normalized name: Benazepril
DrugBank: Benazepril (DB00542)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
Study: NCT00503152
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
Study: NCT00503152
Drug: Benazepril/Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
Study: NCT02244112
Drug: Oprozomib
Normalized name: Oprozomib
DrugBank: Oprozomib (DB11991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.
Study: NCT02244112
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.
Study: NCT00528151
Drug: curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: curcumin 250 mg twice a day in the first group. placebo 1 capsule twice a day in the second group.
Study: NCT03851991
Drug: Arbidol
DrugBank: Umifenovir (DB13609)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03217812
Drug: Velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive velcade 1.3 mg/m\^2, SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9 of Treatment Arm A and B.
Study: NCT01044498
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 8 mg/kg was administered in a single 1-hour infusion on Day 1 of Cycle 2.
Study: NCT00731055
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 doses of Varenicline. 1 capsule of either dose (0mg, 0.5mg, 1mg, 2 mg) in the morning on days at least 5 days apart.
Study: NCT03217812
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive melphalan 9 mg/m\^2 (if serum creatine is \>2 mg/dL at baseline, participants must be administrated 4.5 mg/m\^2 of melphalan, instead of 9 mg/m\^2), orally, once daily on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
Study: NCT03217812
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
Study: NCT03382756
Drug: CKD-337
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test Drug
Study: NCT03931876
Drug: AV-006
Normalized name: AVS-100
DrugBank: AVS-100 (DB18068)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose administration
Study: NCT00710229
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal injection
Study: NCT03217812
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive daratumumab 16 mg/kg as IV infusion or daratumumab SC, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study in Treatment Arm B.
Study: NCT00710229
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal injection
Study: NCT01179048
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
Study: NCT01900730
Drug: Valproic Acid (VPA)
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks.
Study: NCT02107170
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sevoflurane-based general anesthesia
Study: NCT02107170
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: total intravenous anesthesia
Study: NCT02045810
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02045810
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00051025
Drug: ONTAK
Normalized name: Ontak
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006174
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01471808
Drug: CSII, Metformin, Pioglitazone
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CSII for 2\~4 weeks combined with metformin 1.5g/d and pioglitazone 30mg/d for 3 months.
Study: NCT01471808
Drug: CSII, Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CSII for 2\~4 weeks combined with sitagliptin 100mg/d for 3 months
Study: NCT03334617
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab given IV at 1500 mg Q4W ±2 days
Study: NCT01617668
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Commercially available paclitaxel was sourced locally by each study site. Generic paclitaxel could be used for study treatment.~iv 80mg/m2
Study: NCT03401112
Drug: IMR-687
Normalized name: IMRCs
DrugBank: Human Embryonic Stem Cell-derived M Cell (DB15734)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of IMR-687 once daily with or without HU.
Study: NCT03334617
Drug: Vistusertib
Normalized name: Vistusertib
DrugBank: Vistusertib (DB11925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vistusertib (AZD2014) given orally at a dose of 125 mg BD on an intermittent dosing schedule of 2 days on, 5 days off
Study: NCT03334617
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib (AZD2281) given orally at 300 mg BD
Study: NCT03334617
Drug: Oleclumab
Normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleclumab given at dose level 1 for 2 cycles and then dose level 2 thereafter
Study: NCT03334617
Drug: trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab given IV at 1120mg Q3W ±2 days for Module 6 only \& trastuzumab deruxtecan given at 5.4 mg/kg via IV infusion Q3W ±2 days
Study: NCT03334617
Drug: cediranib
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cediranib given orally at 20 mg tablets on an intermittent schedule (5 days on, 2 days off), starting on C1D1
Study: NCT02749513
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01171690
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
Study: NCT00686959
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: infusion over 10 minutes
Study: NCT00686959
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: infusion over 60 minutes with adequate anti-emetic treatment and appropriate hydration per local practice guidelines
Study: NCT00686959
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered per local practice guidelines over a minimum of 30 minutes
Study: NCT00686959
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered over 6-10 minutes infusion per local practice guidelines
Study: NCT00686959
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administered as a 3-hour infusion
Study: NCT00686959
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered per local practice guidelines over 30 minutes
Study: NCT01038856
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib supplied as tablets; oral dose of erlotinib of 150 mg daily to be continued for 16 weeks. Responders will continue for up to 12 months, non-responders will cease taking erlotinib
Study: NCT02020707
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01492400
Drug: dexamethasone Intravitreal Implant
Normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.
Study: NCT01492400
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.
Study: NCT04091971
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will undergo 4 sequential intravenous infusions of ketamine administered over a two week period.~Ketamine is administered at a dose of 0.5mg/kg intravenously as a slow continuous infusion over approximately 40 minutes, with 4 sequential infusions over an approximately two week period (two infusions per week for two weeks).
Study: NCT03334617
Drug: AZD6738 (ceralasertib)
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6738 given at 240 mg twice daily for 14 days on treatment in each 28-day cycle, between Days 1 and 14.
Study: NCT02392793
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally once or twice on day 1 (depending on the dose level), then daily on days 2-6.
Study: NCT02392793
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously daily, days 2-6 immediately following the talazoparib dose.
Study: NCT02392793
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally daily. Dose to be determined after MTD established with talazoparib plus irinotecan.
Study: NCT02392793
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is \>2,000/μL, unless peg-filgrastim is given.
Study: NCT02392793
Drug: Peg-filgrastim
Normalized name: peg-filgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is \>2,000/μL, unless filgrastim is given.
Study: NCT02597998
Drug: 14C-BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01346163
Drug: PF 03654746
Normalized name: PF-03654746
DrugBank: PF-03654746 (DB12201)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive 3 weeks of PF-03654746 and 3 weeks of placebo. PF-03654746 and placebo will be administered in a flexible titration regimen, beginning with 0.5 mg/d. If 0.5 mg/d is well tolerated, the dose will be increased to 1.0 mg/d after 5 days. If 1.0 mg/d is not well tolerated, the dose will be decreased to 0.5 mg/d, with the goal of achieving a stable dose of PF-03654746 within the first two weeks of dosing and avoiding further dose changes during the final week of dosing.
Study: NCT01709032
Drug: Deferasirox and deferiprone
Normalized name: Deferiprone
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01415778
Drug: Casodex 80 mg tablet
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject will receive single dose of Casodex 80 mg tablet
Study: NCT01186796
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Secretagogue combinations are assigned in randomized double-blind order within-subject to include the following four conditions:~(i)L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by 5 mL bolus of NS at 1000 h; (ii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH and Ghrelin (both at dose of 0.3 mcg/kg bolus i.v.) at 1000 h; (iii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH (0.3 μg/kg bolus i.v.) at 1000 h; (iv) L-arginine infusion (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by Ghrelin (0.3 μg/kg bolus i.v.) at 1000 h.~\*\*Ghrelin dosage is based on 70 kg subject.Total exposure of Ghrelin will be 42 mcg total dose for 2 subject visits (21 mcg per visit).
Study: NCT03633526
Drug: IVA
Normalized name: Viva
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVA mono tablet.
Study: NCT00684450
Drug: Standard administration of protamine
Normalized name: protamines
DrugBank: Protamine sulfate (DB09141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.3 mg of Protamine for 100u héparine
Study: NCT02962297
Drug: Vitamin E softgel
Normalized name: Lipotriad Dry Eye Omega-3 1400mg + Vitamin E Softgel
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
Study: NCT02253797
Drug: 14C-Tipranavir
Normalized name: 14C-TIPRANAVIR
DrugBank: Tipranavir C-14 (DB15108)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00811759
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00811759
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00113230
Drug: Avastin (Bevacizumab, RHUMAB VEGF)
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting Dose 5 mg/kg intravenously on day one of radiotherapy, given every 2 weeks +/- 2 days for a total of 3 doses.
Study: NCT02307487
Drug: 120 mg MMC in 90ml gel
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
Study: NCT02307487
Drug: 140 mg MMC in 90ml gel
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
Study: NCT02307487
Drug: 160 mg MMC in 90ml gel
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 160 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
Study: NCT02307487
Drug: 120 mg MMC in 60ml gel
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
Study: NCT02307487
Drug: 140 mg MMC in 60ml gel
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
Study: NCT02307487
Drug: 160 mg MMC in 60ml gel
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 160 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
Study: NCT02253797
Drug: Tipranavir
Normalized name: Tipranavir
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02253797
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00654017
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral sildenafil citrate at an initial dose of 25 mg, which could have been up-titrated to 50 mg at Visit 3 based on the patient's efficacy, safety and tolerability responses; at Visits 4 and 5, the dose could remain the same, be increased to 100 mg, or decreased to 25 mg depending on the safety, efficacy, and tolerability
Study: NCT00478231
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.
Study: NCT00667875
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone (25mg or 50 mg per titration schedule)
Study: NCT00667875
Drug: Naltrexone + Aripiprazole
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)
Study: NCT03799731
Drug: GM102
Normalized name: Glatiramer acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GM102 7 mg/kg weekly
Study: NCT03799731
Drug: GM102 expansion
Normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM102 7 mg/kg weekly after a loading dose of 10 mg/kg q1w during 28-day cycle 1
Study: NCT01300650
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 100 mg subcutaneous injection daily
Study: NCT00227292
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
Study: NCT02429726
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered by intra chest cavity infusion
Study: NCT02429726
Drug: rAdp53 plus cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant adenoviral p53 human gene combined with cisplatin will be administered by intra chest cavity infusion
Study: NCT00005798
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be given at a dose of 267 mg/m2 in D5 W IV over one hour daily on days -6, -5, and -4. (Total dose 800 mg/m2)
Study: NCT00005798
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 500 mg/m2 )
Study: NCT02403362
Drug: EPO-018B
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03434340
Drug: Granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg intravenous injection
Study: NCT03434340
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4mg intravenous injection
Study: NCT02224313
Drug: oral progesterone 100 mg
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: one tablet of oral progesterone 100 mg once a day for 14 days
Study: NCT01416662
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03334617
Drug: AZD6738 (ceralasertib)
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6738 given orally at 240mg twice daily for 14 days in each 28 day cycle (starting from Cycle 1) between Days 15-28